MicroRNAs (miRNAs) play an important role in modulating neuronal stress responses, but their impact on neuroprotection has been poorly studied. Multiple sclerosis (MS) is the most common inflammatory disease affecting the central nervous system. Researchers have recently attempted to identify potential miRNAs that play a protective role in neuroinflammation.
One of the difficulties for preventing the evolution of a tumor is that cancer progression can be promoted by undifferentiated or migrating cells whose states could follow different directions. At the 40th edition of Barcelona Biomed conferences at the Institute for Research in Biomedicine (IRB Barcelona), which took place from Nov. 27 to 29, 2023, and is entitled “Cancer in Context: Cellular, Tissue, and Organismal Determinants of Malignant Fates,” Angela Nieto presented her latest data on epithelial-to-mesenchymal transition (EMT).
Launching a company based on knowledge that “the fundamental principle that most people hold to be true is off by a trillion” is a rare opportunity, said Jake Rubens, co-founder and president of Quotient Therapeutics Inc., a company that emerged from stealth this week, backed by two years of platform development and a $50 million investment from Flagship Pioneering.
Shanghai Institute of Organic Chemistry has described oleanamide derivatives acting as Kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2)/antioxidant response element (ARE) pathway activators reported to be useful for the treatment of amyotrophic lateral sclerosis, diabetes, multiple sclerosis, renal disorders, Huntington's disease, Parkinson's disease, autoimmune disease and Alzheimer's disease, among others.
DE Shaw Research LLC has identified transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of pain, fibrosis, autoimmune disease, neurological, dermatological, cardiovascular, respiratory and gastrointestinal disorders, among others.
Researchers from Centre National de la Recherche Scientifique, Inserm, Université Claude Bernard and Université Jean Monnet have synthesized peptides acting as amyloid-β (Aβ) protein aggregation inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, cerebral amyloid angiopathy, Down syndrome, Parkinson's disease, Alzheimer's disease and motor neuron disease.
Korea Research Institute of Chemical Technology has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) and mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) inhibitors reported to be useful for the treatment of Parkinson's disease, viral infection, cancer, tuberculosis and non-alcoholic steatohepatitis.
Triple-negative breast cancer (TNBC) is the most aggressive breast tumor subtype and despite treatment advances, still has shorter median overall survival rates and higher recurrence and metastatic rates than other subtypes, due to resistance to chemotherapy.
RSS
